GGHC
PRVL

Gilder Gagnon Howe & Co’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed – – 367
2020
Q3 		$0 Hold
5
– – ﹤0.01% 358
2020
Q2 		$0 Hold
5
– – ﹤0.01% 327
2020
Q1 		$0 Hold
5
– – ﹤0.01% 313
2019
Q4 		$0 Hold
5
– – ﹤0.01% 315
2019
Q3 		$0 Sell
5
-29,475
-100% -$334K ﹤0.01% 312
2019
Q2 		$389K Buy
+29,480
New +$430K ﹤0.01% 250

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gilder Gagnon Howe & Co's PRVL Position: Q4 2020 in Review

Gilder Gagnon Howe & Co sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 5 shares.

Gilder Gagnon Howe & Co first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $389K in Q2 2019. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • Gilder Gagnon Howe & Co reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 5 Prevail Therapeutics Inc. Common Stock shares in Q4 2020.
  • Gilder Gagnon Howe & Co first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
  • Gilder Gagnon Howe & Co's Prevail Therapeutics Inc. Common Stock position peaked at $389K in Q2 2019.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2020, filed 16 Feb 2021.